GW Pharmaceuticals PLC- (GWPH) Lifted to “Hold” at BidaskClub

GW Pharmaceuticals PLC- (NASDAQ:GWPH) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a research report on Friday. Cantor Fitzgerald decreased their price target on shares of GW Pharmaceuticals PLC- from $235.00 to $211.00 and set an “overweight” rating for the company in a research report on Wednesday, August 8th. ValuEngine downgraded shares of GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a report on Thursday, August 2nd. Bank of America lifted their price objective on shares of GW Pharmaceuticals PLC- from $170.00 to $200.00 and gave the stock a “buy” rating in a report on Tuesday, June 26th. Finally, Cowen reaffirmed a “buy” rating and issued a $165.00 price objective on shares of GW Pharmaceuticals PLC- in a report on Wednesday, May 9th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. GW Pharmaceuticals PLC- currently has a consensus rating of “Buy” and an average price target of $175.29.

GWPH stock opened at $134.96 on Friday. GW Pharmaceuticals PLC- has a twelve month low of $96.42 and a twelve month high of $164.76. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.67 and a quick ratio of 11.22. The company has a market cap of $3.77 billion, a PE ratio of -19.42 and a beta of 2.55.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last released its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.40) by $1.14. GW Pharmaceuticals PLC- had a negative net margin of 1,392.61% and a negative return on equity of 47.65%. The business had revenue of $3.46 million during the quarter, compared to the consensus estimate of $2.00 million. analysts anticipate that GW Pharmaceuticals PLC- will post -9.02 EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the business. WealthTrust Fairport LLC acquired a new position in GW Pharmaceuticals PLC- in the first quarter worth $104,000. Stratos Wealth Partners LTD. boosted its holdings in GW Pharmaceuticals PLC- by 216.0% in the first quarter. Stratos Wealth Partners LTD. now owns 948 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 648 shares during the period. Envestnet Asset Management Inc. acquired a new position in GW Pharmaceuticals PLC- in the second quarter worth $119,000. Cowen Prime Services LLC boosted its holdings in GW Pharmaceuticals PLC- by 708.0% in the second quarter. Cowen Prime Services LLC now owns 1,010 shares of the biopharmaceutical company’s stock worth $141,000 after purchasing an additional 885 shares during the period. Finally, NumerixS Investment Technologies Inc acquired a new position in GW Pharmaceuticals PLC- in the second quarter worth $166,000. 72.78% of the stock is owned by hedge funds and other institutional investors.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.

See Also: How do investors use RSI to grade stocks?

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply